It has been estimated that, if HAART is accessible to all patients with CD4+ < 200 cells/μl and would restore optimal immune responses specific to Mtb, the cumulative incidence of TB would decrease by 22% over 20 years[44]. This evidence concerns the gene CD4 and tuberculosis.